These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27832239)

  • 21. Mycobacterium fortuitum: an iatrogenic cause of soft tissue infection in surgery.
    Muthusami JC; Vyas FL; Mukundan U; Jesudason MR; Govil S; Jesudason SR
    ANZ J Surg; 2004 Aug; 74(8):662-6. PubMed ID: 15315567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.
    Nash KA; Zhang Y; Brown-Elliott BA; Wallace RJ
    J Antimicrob Chemother; 2005 Feb; 55(2):170-7. PubMed ID: 15590712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrido-1,2-thiazines and their in vitro antibacterial evaluation.
    Malinka W; Gamian A; Redzicka A; Swiatek P
    Acta Pol Pharm; 2008; 65(1):71-4. PubMed ID: 18536176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
    Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
    Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.
    Shen GH; Wu BD; Wu KM; Chen JH
    Antimicrob Agents Chemother; 2007 May; 51(5):1849-51. PubMed ID: 17353252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and studies on antibacterial activity of pyrido[3,2-e]-1,2-thiazines and related derivatives.
    Malinka W; Gamian A; Szcześniak-Siega B
    Acta Pol Pharm; 2008; 65(5):557-63. PubMed ID: 19051602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venous catheter-associated bacteremia caused by rapidly growing mycobacteria at a medical center in central Taiwan.
    Chang CY; Tsay RW; Lin LC; Liu CE
    J Microbiol Immunol Infect; 2009 Aug; 42(4):343-50. PubMed ID: 19949759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Microbiological properties of M. porcinum isolated from a patient with impairments in IL-12/IFN-gamma pathway].
    Kazumi Y; Maeda S; Udagawa T; Sugawara I; Kamiya H
    Kekkaku; 2008 Nov; 83(11):717-23. PubMed ID: 19086435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum.
    Ramón-García S; Martín C; Aínsa JA; De Rossi E
    J Antimicrob Chemother; 2006 Feb; 57(2):252-9. PubMed ID: 16373429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of a widespread cutaneous Mycobacterium fortuitum infection with levofloxacin.
    Nakagawa K; Tsuruta D; Ishii M
    Int J Dermatol; 2006 Sep; 45(9):1098-9. PubMed ID: 16961521
    [No Abstract]   [Full Text] [Related]  

  • 31. In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.
    Vera-Cabrera L; Brown-Elliott BA; Wallace RJ; Ocampo-Candiani J; Welsh O; Choi SH; Molina-Torres CA
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4027-9. PubMed ID: 17015632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and laboratory features of Mycobacterium porcinum.
    Wallace RJ; Brown-Elliott BA; Wilson RW; Mann L; Hall L; Zhang Y; Jost KC; Brown JM; Kabani A; Schinsky MF; Steigerwalt AG; Crist CJ; Roberts GD; Blacklock Z; Tsukamura M; Silcox V; Turenne C
    J Clin Microbiol; 2004 Dec; 42(12):5689-97. PubMed ID: 15583300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic studies on microbial cross-resistance to toxic agents. III. Cross-resistance of Mycobacterium ranae to twenty-eight antimycobacterial agents.
    SZYBALSKI W; BRYSON V
    Am Rev Tuberc; 1954 Feb; 69(2):267-79. PubMed ID: 13114644
    [No Abstract]   [Full Text] [Related]  

  • 34. [Susceptibility to antimicrobial agents of rapidly growing mycobacteria].
    Ruiz-Aragón J; García-Agudo L; Flores S; Rodríguez MJ; Marín P; García-Martos P
    Rev Esp Quimioter; 2007 Dec; 20(4):429-32. PubMed ID: 18563216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro drug susceptibility of Mycobacterium other than tubercle bacilli.
    Imwidthaya P; Komolpis P; Suthiravitayavaniz K; Rienthong S
    J Med Assoc Thai; 1990 Aug; 73(8):438-42. PubMed ID: 2262746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in the kidneys in patients with successive findings of Mycobacterium xenopi and Mycobacterium fortuitum in the urine--report of 16 cases]].
    Lovodić-Sivcev B; Vukelić A
    Med Pregl; 1999; 52(9-10):334-42. PubMed ID: 10624381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of glutathione and N-acetyl cysteine on the antimycobacterial efficacy of isoniazid on Mycobacterium fortuitum in vitro.
    Coleman MD; Aerry R; Wanogho E; Khan NB; Lambert PA; Rathbone DL
    J Chemother; 2006 Dec; 18(6):665-6. PubMed ID: 17267348
    [No Abstract]   [Full Text] [Related]  

  • 38. [In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria].
    Zerbini E; Andreu D; Tonarelli G; Sequeira MD
    Rev Argent Microbiol; 2006; 38(4):221-3. PubMed ID: 17370578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unusual clinical presentation of Mycobacterium fortuitum infection in an immunocompetent woman.
    Serra C; Loi G; Saddi B; Pautasso M; Manzin A
    J Clin Microbiol; 2007 May; 45(5):1663-5. PubMed ID: 17360837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Resistance of Mycobacterium fortuitum against varied physical factors and its survival in different surroundings].
    Zhuang B; Wu C; Lin G
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Nov; 24(11):679-81. PubMed ID: 16136908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.